Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 97

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 97
---
 | overall performance of the equity markets; |

| • |     | changes in the market valuations and stock market price and volume fluctuations of comparable companies and, in particular, 
 those that operate in the biopharmaceutical industry;                                                                       |

| • |     | publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research 
 coverage by securities analysts;                                                                                           |

| • |     | announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, capital 
 commitments or divestitures;                                                                                          |

| • |     | third-party publications and discussions about our business on social media, forums and other websites; |

| • |     | recruitment or departure of key personnel; |

| • |     | trading volume of our common stock; |

| • |     | sales of common stock by us or our stockholders in the future; |

| • |     | disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to 
 obtain patent protection for our product candidates;                                                                    |

| • |     | significant lawsuits, including patent or stockholder litigation; |

| • |     | changes in the structure of healthcare payment systems; |

| • |     | changes in accounting standards, policies, guidelines, interpretations or principles; |

| • |     | regulatory or legal developments in the U.S. and foreign countries; |

| • |     | general political and economic conditions; and |

| • |     | other events or factors, many of which are beyond our control. |

The stock market in general, and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the risks described in this section, or any of a broad range of other risks, could have a material adverse impact on the market price of our common stock. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted, could result in substantial costs and divert management’s attention and resources. We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. If our common stock is listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such